Ellen Matloff on Oophorectomy Timing for BRCA Carriers

Ellen T. Matloff, MS, CGC
Published: Monday, Mar 10, 2014

Ellen T. Matloff, MS, CGC, director, Yale Cancer Genetic Counseling Program at the Yale School of Medicine/Yale Cancer Center, discusses the proper age for a carrier of the BRCA1 or BRCA2 mutation to undergo oophorectomy.

Recent data has been released showing that BRCA1 or BRCA2 mutation carriers who undergo an oophorectomy at age 35 have a longer life expectancy. Matloff says she was concerned with the way the data were reported because it could have appeared that 35 was a “magic age.”

In some patients, such as those with a family history of ovarian cancer that is diagnosed before age 35, it may make sense to implement risk-reduction strategies earlier on. In other patients, such as those who are not done with child bearing, it’s possible to wait.

Matloff says she recommends that all BRCA carriers discuss their mutation, personal and family history, and treatment options with a certified genetic counselor.

<<< View more from the 2014 Miami Breast Cancer Conference

Ellen T. Matloff, MS, CGC, director, Yale Cancer Genetic Counseling Program at the Yale School of Medicine/Yale Cancer Center, discusses the proper age for a carrier of the BRCA1 or BRCA2 mutation to undergo oophorectomy.

Recent data has been released showing that BRCA1 or BRCA2 mutation carriers who undergo an oophorectomy at age 35 have a longer life expectancy. Matloff says she was concerned with the way the data were reported because it could have appeared that 35 was a “magic age.”

In some patients, such as those with a family history of ovarian cancer that is diagnosed before age 35, it may make sense to implement risk-reduction strategies earlier on. In other patients, such as those who are not done with child bearing, it’s possible to wait.

Matloff says she recommends that all BRCA carriers discuss their mutation, personal and family history, and treatment options with a certified genetic counselor.

<<< View more from the 2014 Miami Breast Cancer Conference




View Conference Coverage
Online CME Activities
TitleExpiration DateCME Credits
Oncology Best Practice™: Expert Perspectives to Incorporate Evidence on PARP Inhibitors into Practice and Optimize the Medical Management of Ovarian CancerOct 31, 20181.0
Community Practice Connections™: Precision Medicine for Community Oncologists: Assessing the Role of Tumor-Testing Technologies in Cancer CareNov 30, 20181.0
Publication Bottom Border
Border Publication
x